

Olivera Đokić,* Slobodan Tomić, Ivana Petrović, Dragana Šarenac

ZNAČAJ DIJAGNOSTIKE POREMEĆAJA TIREOIDNE FUNKCIJE: UTICAJ SUPKLINIČKIH POREMEĆAJA NA BOLESTI SRCA

Sažetak: Supklinička oboljenja štitaste žlezde na više načina povezana su sa kardiovaskularnim bolestima. Najčešći srčani poremećaji kod bolesnika sa supkliničkom hipotireozom su dijastolna disfunkcija leve komore i smanjen funkcionalni kapacitet srca, te time oslabljen kardiopulmonalni odgovor pri naporu. Prema publikovanim podacima, supklinička hipotireoza u vezi je sa povećanim nivoom holesterola, povećanim rizicima od koronarne bolesti srca i bolesti aorte, te povećanim kardiovaskularnim mortalitetom.

Bolesnici sa supkliničkom hipertireozom imaju povećan rizik od nastanka atrijalne fibrilacije, što dalje može dovesti do tromboembolijskih događaja; disfunkcija može dovesti do srčane dekompenzacije i hronične srčane slabosti.

S obzirom na to da su supklinička oboljenja štitaste žlezde obično progresivna, jasan je veliki značaj pravovremene funkcionalne dijagnostike lečenju sprečavanja kardiovaskularnih komplikacija.

Ključne reči: tireoidna žlezda, srce, hipofunkcija, hiperfunkcija

Abstract: Subclinical thyroid disease in many ways are associated with cardiovascular disease. The most common cardiovascular disorders in patients with subclinical hypothyroidism are diastolic dysfunction and reduced functional capacity of the heart, and thus weakened cardiopulmonary response during exercise. According to published data subclinical hypothyroidism is associated with abnormal cholesterol levels, increased

* Institut za kardiovaskularne bolesti „Dedinje“; Milana Tepica br.1, Beograd, Srbija, e-mail: oljaisara@gmail.com.

risk of coronary heart disease and diseases of the aorta, and increased cardiovascular mortality.

Patients with subclinical hyperthyroidism are at increased risk of atrial fibrillation, which may lead to thromboembolic events; increased left ventricular mass is related to the sudden cardiac death; significant diastolic dysfunction can lead to cardiac decompensation and chronic heart failure.

Given that subclinical thyroid disease is usually progressive, is a clear great importance of timely functional diagnostics in the treatment and prevention cardiovascular complications.

Key words: thyroid, subclinical, hypothyroidism, hyperthyroidism

Uvod: Eksperimentalni i klinički dokazi čvrsto podržavaju koncept da tireoidni hormoni imaju fundamentalnu ulogu u kardiovaskularnoj homeostazi, kako u fiziološkim, tako i u patološkim uslovima.

Postoje dokazi da pacijenti s akutnim i hroničnim srčanim bolestima, kao i oni koji podležu kardiohirurgiji, mogu imati izmenjen periferni metabolizam tireoidnih hormona, koji potom može biti u vezi sa promenom srčanih funkcija. Disfunkcija štitne žlezde prouzrokuje značajne promene u kardiovaskularnom sistemu. Opsežni dokazi indikuju da kardiovaskularni sistem odgovara na minimalne, ali perzistentne promene u nivou cirkulišućih hormona, što je tipično za osobe sa supkliničkom tireoidnom disfunkcijom.

Efekti supkliničke hipotireoze na kardiovaskularni sistem

Uopšteno, tokom mirovanja broj otkucaja srca i krvni pritisak kod pacijenata sa supkliničkom hipotireozom su normalni. Pojedina ispitivanja pokazala su i značajnije hipofunkcionalne abnormalnosti u parasimpatičkom nervnom sistemu, te povećanje prevalence arterijske hipertenzije kod ovih pacijenata. Najznačajnija srčana abnormalnost prisutna kod pacijenata sa supkliničkom hipotireozom jeste dijastolna disfunkcija leve komore, koja se karakteriše usporenom relaksacijom miokarda i oslabljenim ranim punjenjem komore. Promene su prisutne kako i miru, tako i tokom opterećenja. Često je ovo u vezi sa različitim stepenom slabosti sistolne funkcije leve komore, što postaje jače izraženo tokom opterećenja.

Studije su pokazale da pacijenti sa supkliničkom hipotireozom imaju na nekoliko načina oslabljen kardiopulmonalni odgovor pri fizičkom opterećenju. Studija, kojom je ispitivana prognostička uloga supkliničke hipotireoze kod 400 pacijenata sa hroničnom srčanom slabošću (Lacoviello et al, Univerzitetska klinika, Bari) obuhvatala je dijagnostičke procedure (EKG, ECHO srca, ERGO-test), kao i analize krvi kojim su

ispitivani: renalna funkcija, elektroliti, gram-hemoglobin, NT-proBNP, fT3, fT4, TSH nivo, pokazala je da je samo praćenje nivoa TSH signifikantno za pogoršanje hronične srčane slabosti, tj. da je TSH nezavisan prediktor pogoršanja hronične srčane slabosti.

Hipotireoza, naročito u supkliničkoj formi, česta je kod pacijenata sa hroničnom srčanom slabošću koji primaju Amiodaron. Najnovije preporuke u tretmanu takvih pacijenata jesu primena supstitucione terapije Levotiroxin-om, bez potrebe isključivanja Amiodarona iz terapije, uz redovno testiranje tireoidne funkcije.

Studije su pokazale da je SY. LOW T3 jedan nezavisan prediktor i ranog i kasnog preživljavanja pacijenata sa akutnim srčanim udarom, kao i da je snižen fT3 nivo prediktor za jednosudovnu i za višesudovnu koronarnu bolest.

Postoji jaka veza između supkliničke hipotireoze i aterosklerotske kardiovaskularne bolesti, nezavisno od tradicionalnih faktora rizika: hiperholesterolemije, hipertenzije, pušenja, šećerne bolesti – ROTTERDAM STUDY.

Supklinička hipotireoza u vezi je sa aterogenim lipidnim profilom: povećanjem nivoa ukupnog holesterola, LDL-a, kao i oksidisanih lipoproteina male gustine u cirkulaciji. Takođe, deluje na profil hemostaze, tj. hiperkoagulabilni status. Kod pacijenata sa supkliničkom hipotireozom registrovano je i smanjenje endotelijum zavisnih medijatora vazodilatacije, koji su rani marker ateroskleroze.

Značajno je da se većina kardiovaskularnih i metaboličkih abnormalnosti poboljšava ili čak normalizuje kada se pacijenti sa supkliničkom hipotireozom tretiraju sa L-T4. Da li pacijente sa supkliničkom hipotireozom treba tretirati na ovaj način ostaje predmet usaglašavanja.

Efekti supkliničke hipertireoze na kardiovaskularni sistem

Kada su u pitanju efekti supkliničke hipertireoze na kardiovaskularni sistem treba uzeti u obzir da se najčešće radi o *egzogenoj* supkliničkoj hipertireozii.

Najznačajnije abnormalnosti nađene kod pacijenata sa supkliničkom hipertireozom su: povećanje frekvence, povećanje prevalencije supraventrikularnih aritmija, uvećanje mase leve komore, lako povećanje sistolne funkcije leve komore, kao i oslabljena dijasolna funkcija kao posledica usporene relaksacije miokarda.

Povećanje mase leve komore posledica je zadebljanja zidova leve komore, bez povećanja dimenzija šupljine, tzv. koncentrični remodeling.

Hipertrofija leve komore više korespondira sa dužinom trajanja supkliničke hipertireoze nego sa nivoom cirkulišućih tireoidnih hormona. Mehanizam odgovoran za hipertrofiju leve komore još nije u potpunosti rasvetljen, verovatno nastaje kao odgovor na hronično hemodinamsko opterećenje usled blagog hiperkinetskog kardiovaskularnog statusa (usporena relaksacija miokarda i oslabljeno punjenje leve komore).

Postoje sugestije da ova dijasolna disfunkcija jeste rezultat izmenjenog intracelularnog vezivanja kalcijuma usled redukovane ekspresije kalcijum ATP-aze na sar-

koplazmatskom retikulumu ili povećane ekspresije phospholambana-a, sa odloženim preuzimanjem kalcijuma od strane sarkoplazmatskog retikuluma. Postavlja se hipoteza da bi, u dužem periodu efekti metabolizma kalcijuma na hronično opterećenje srca trebalo da nadjača one prouzrokovane tireoidnim hormonima.

Abnormalnosti morfologije i funkcije leve komore značajno se smanjuju prevođenjem pacijenata u euriotsni status, kao i primenom lekova iz grupe beta-blokatora. Ovo potvrđuje hipotezu da je uključivanje srca u supkliničku hipertireozu reverzibilno i uglavnom determinisano funkcionalnim mehanizmima.

Postoje dokazi da je supklinička hipertireoza u vezi sa povećanjem kardiovaskularnog mortaliteta. Nekoliko faktora korelira sa ovim fenomenom: pacijenti sa supkliničkom hipertireozom, posebno stariji, imaju povećan rizik od nastanka atrijalne fibrilacije, što može uticati na povećanje incidence tromboembolijskih događaja; pokazano je da je povećanje mase LV *per se*, kao i srčane frekvence u vezi sa povećanim rizikom od nagle srčane smrti; poznato je da dijastolna disfunkcija može vremenom dovesti do razvoja ozbiljne dijastolne disfunkcije koja, posebno kod starijih, može prouzrokovati srčanu dekompenzaciju i hroničnu srčanu slabost.

Terapeutske indikacije bile bi da kod kardiovaskularnih pacijenata, koji imaju benignu tireoidnu bolest, treba izbeći ili korigovati supkliničku hipertireozu, a kod bolesnika kod kojih je supklinički hipertireoidizam terapeutska indikacija (npr. diferencirani tireoidni kancer) L-T4 se primenjuje u manjim dozama od dovoljnih za postizanje stabilne TSH supresije, eventualno u kombinaciji sa beta-blokatorima.

Supklinička hipertireoza može biti očekivana:

- kod svih pacijenata sa istorijom atrijalne fibrilacije, naročito kod starijih
- pacijenata sa pogoršanjem angioznih tegoba
- pacijenata sa srčanom dekompenzacijom.

Zaključak

Imajući u vidu da simptomi i znaci od strane kardiovaskularnog sistema mogu biti jedina manifestacija tireoidne disfunkcije, kao i da perzistentna supklinička tireoidna disfunkcija može značajno povećati kardiovaskularni rizik, tireoidni status trebalo bi biti sistematski ispitivan kod: svih pacijenata sa novodijagnostikovanom kardiovaskularnom bolešću, kao i kod pacijenata sa pogoršanjem kardiovaskularne bolesti, posebno starije životne dobi.

Literatura

Amasyali B, Barrin C, et al. 2011, Supra-His complete atrioventricular block in a patient with subclinical hyperthyroidism. Turk Kardiyol Dern Ars 39(8):693-6.

- Andersen S, Pedersen KM, Brunn NH, et al. 2002, Narrow individual variations in serum T4 and T3 in normal subjects: a clue to understanding of subclinical thyroid disease. *J Clin Endocrinol Metab* 87:1068–1072.
- Alevizaki M, Syneton M, et al. 2007. Low triiodothyronine: a strong predictor of outcome in acute stroke patients. *Eur J Clin Invest*. 37(8):651-7.
- Auer J, Scheibner P, Mische T, et al. 2001. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. *Am Heart J* 142:838–842.
- Bengel FM, Nekolla SG, Ibrahim T, et al. 2000, Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. *J Clin Endocrinol Metab* 85:1822–1827.
- Bettendorf M, Schmidt KG, Tiefenbacher U, et al. 1997. Transient secondary hypothyroidism in children after cardiac surgery. *Pediatr Res* 41:375–379.
- Bettendorf M, Schmidt KG, Grulich-Henn J, et al. 2000, Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomized, placebo-controlled study. *Lancet* 356:529–534.
- Bindels AJ, Westendorp RG, Frolich M, et al. 1999, The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? *Clin Endocrinol* 50:217–220.
- Biondi B, Fazio S, Carella C, et al. 1993, Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* 77:334–337.
- Biondi B, Fazio S, Carella C, et al. 1994, Control of adrenergic overactivity by B-blockade improves quality of life in patients receiving long term suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* 78:1028–1033.
- Biondi B, Fazio S, Cuocolo A, et al. 1996, Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* 81:4224–4228.
- Biondi B, Fazio S, Palmieri EA, et al. 1999a, Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. *J Clin Endocrinol Metab* 84:2064–2067.
- Biondi B, Fazio S, Palmieri EA, et al. 1999, Effects of chronic subclinical hyperthyroidism on cardiac morphology and function. *Cardiologia* 44:443–449.
- Biondi B, Palmieri EA, Fazio S, et al. 2000, Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. *J Clin Endocrinol Metab* 85:4702–4705.
- Biondi B, Palmieri EA, Lombardi G, et al. 2002a, Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the thyroid hormone & the cardiovascular system 45.
- Downloaded from rphr.endojournals.org by on May 26, 2012 regulation of cardiac performance in human hyperthyroidism. *J Clin Endocrinol Metab* 87:968–974.
- Biondi B, Fazio S, Palmieri EA, et al. 2002, Mortality in elderly patients with subclinical hyperthyroidism. *Lancet* 359:799–800.
- Biondi B, Palmieri EA, Lombardi G, et al. 2002, Effects of subclinical thyroid dysfunction on the heart. *Ann Intern Med* 137:904–914.
- Brent GA 1994, The molecular basis of thyroid hormone action. *N Engl J Med* 331:847–853.

- Brenta G, Mutti LA, Schnitman M, et al. 2003, Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. *Am J Cardiol* 2003 91:1327–1330.
- Cacciatori V, Bellavere F, Pezzarossa A, et al. 1996, Power spectral analysis of heart rate in hyperthyroidism. *J Clin Endocrinol Metab* 81:2828–2835
- Canaris GJ, Manowitz NR, Mayor G, et al. 2000, The Colorado thyroid disease prevalence study. *Arch Intern Med* 160:526–534.
- Ching GW, Franklyn JA, Stallard TJ, et al. 1996, Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. *Heart* 75:363–368.
- Chu JW, Crapo LM 2001, The treatment of subclinical hypothyroidism is seldom necessary. *J Clin Endocrinol Metab* 86:4591–4599.
- Cimochowski GE, Harostock MD, Foldes PG 1997 Minimal operative mortality in patients undergoing coronary artery bypass with significant left ventricular dysfunction by maximization of metabolic and mechanical support. *J Thorac Cardiovasc Surg* 113:655–666.
- Coceani, Lervasi G, et al. 2009, Thyroid hormone and CAD :from clinical correlations to prognostic implications.32(7):380-5.
- Danese MD, Ladenson PW, Meinert CL, et al. 2000, Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. *J Clin Endocrinol Metab* 85:2993–3001.
- Davis PJ, Davis FB 1993, Acute cellular actions of thyroid hormone and myocardial function. *Ann Thorac Surg* 56(suppl):S16–S23.
- Dernellis J, Panaretou M 2002, Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. *Am Heart J* 143:718–724.
- Di Bello V, Monzani F, Giorgi D, et al. 2002, Ultrasonic myocardial textural analysis in subclinical hypothyroidism. *J Am Soc Echocardiogr* 13:832–840.
- Dillmann WH 1990, Biochemical basis of thyroid hormone action in the heart. *Am J Med* 88:626–630.
- Duntas LH 2002, Thyroid disease and lipids. *Thyroid* 12:287–293.
- Duntas LH, Mantzou E, Koutras DA 2002, Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. *Thyroid* 12:1003–1007.
- Everts ME, Verhoeven FA, Bezstarosti K, et al. 1996, Uptake of thyroid hormone in neonatal rat cardiac myocytes. *Endocrinology* 137:4235–4242.
- Faber J, Petersen L, Wiinberg N, et al. 2002, Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. *Thyroid* 12:319–324.
- Fazio S, Biondi B, Carella C, et al. 1995, Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of blockade. *J Clin Endocrinol Metab* 80:2222–2226.
- Fazio s. et al. Downloaded from rphr.endojournals.org by on May 26, 2012 Feldman T, Borow KM, Sarne DH, et al. 1986 Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contractile state. *J Am Coll Cardiol* 7:967–974.
- Fletcher AK, Weetman AP 1998, Hypertension and hypothyroidism. *J Hum Hypertens* 12:79–82.

- Foldes J, Istvanfy M, Halmagyi H, et al. 1987, Hypothyroidism and the heart. Examination of left ventricular function in subclinical hypothyroidism. *Acta Med Hung* 44:337–347.
- Fommei E, Iervasi G 2002, The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. *J Clin Endocrinol Metab* 87:1996–2000.
- Franklyn JA, Gammage MD, Ramsden DB, et al. 1984, Thyroid status in patients after acute myocardial infarction. *Clin Sci (Lond)* 67:585–590.
- Fredlund BO, Olsson SB 1983, Long QT interval and ventricular tachycardia of “torsade de pointe” type in hypothyroidism. *Acta Med Scand* 213:231–235.
- Friedman MJ, Okada RD, Ewy GA, et al. 1982, Left ventricular systolic and diastolic function in hyperthyroidism. *Am Heart J* 104:1303–1308.
- Gheri RG, Pucci P, et al. 2004, Clinical, biochemical and therapeutical aspects of Amiodarone-induced hypothyroidism in geriatric patients with cardiac arrhythmias. *Arch Gerontol. Geriatr.*38(1):27-36.
- Gick GG, Melikian J, Ismail-Beigi F 1990, Thyroidal enhancement of rat myocardial Na,K-ATPase: preferential expression of alpha 2 activity and mRNA abundance. *J Membr Biol* 115:273–282.
- Gilligan DM, Ellenbogen KA, Epstein AE 1996, The management of atrial fibrillation. *Am J Med* 101:413–421.
- Greenland P, Daviglius ML, Dyer AR, et al. 1999, Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. *Am J Epidemiol* 149:853–862.
- Haider AW, Larson MG, Benjamin EJ, et al. 1998, Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. *J Am Coll Cardiol* 32:1454–1459.
- Hak AE, Pols HAP, Visser TJ, et al. 2000, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Ann Intern Med* 132:270–278.
- Hamilton MA, Stevenson LW, Luu M, et al. 1990, Altered thyroid hormone metabolism in advanced heart failure. *J Am Coll Cardiol* 16:91–95.
- Hamilton MA, Stevenson LW, Fonarow GC, et al. 1998, Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. *Am J Cardiol* 81:443–447.
- Hoit BD, Khoury SF, Shao Y, et al. 1997, Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. *Circulation* 96:592–598.
- Holland FW II, Brown PS Jr, Weintraub BD, et al. 1991, Cardiopulmonary bypass and thyroid function: a “euthyroid sick syndrome.” *Ann Thorac Surg* 52:46–50.
- Huber G, Staub JJ, Meier C, et al. 2002, Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. *J Clin Endocrinol Metab* 87:3221–3226.
- Kahaly GJ 2000, Cardiovascular and atherogenic aspects of subclinical hypothyroidism. *Thyroid* 10:665–679.

- Kahaly GJ, Nieswandt J, Wagner S, et al. 1998, Ineffective cardiorespiratory function in hyperthyroidism. *J Clin Endocrinol Metab* 83:4075–4078.
- Kahaly GJ, Wagner S, Nieswandt J, et al. 1999, Stress echocardiography in hyperthyroidism. *J Clin Endocrinol Metab* 84:2308–2313.
- Kaminski G, Makowski K, et al. 2012, The influence of subclinical hyperthyroidism on blood pressure, heart rate variability and prevalence of arrhythmias. *22(5):454-60.*
- Katzeff HL, Powell SR, Ojamaa K 1997, Alteration in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. *Am J Physiol* 273:E951–E956.
- Kinugawa K, Minobe WA, Wood WM, et al. 2001, Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. *Circulation* 103:1089–1094.
- Kiss E, Jakab G, Kranias EG, et al. 1994, Thyroid hormone induced alteration in phospholamban protein expression: regulatory effects on sarcoplasmic transport and myocardial relaxation. *Circ Res* 75:245–251.
- Kiss E, Brittsan AG, Elds I, et al. 1998, Thyroid hormone-induced alterations in phospholamban-deficient mouse hearts. *Circ Res* 83:608–613.
- Klein I 1988, Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol. *Endocrinology* 123:203–210.
- Klein I 1989, Thyroid hormone and high blood pressure. In: Laragh JH, Brenner BM, Kaplan NM, eds. *Endocrine Mechanisms in Hypertension*, vol. 2. New York: Raven Press; 61–80.
- Klein I, Levey GS 1984, Unusual manifestations of hypothyroidism. *Arch Intern Med* 144:123–128.
- Klein I, Ojamaa K 1998, Thyroid hormone treatment of congestive heart failure. *Am J Cardiol* 81:490–491.
- Klein I, Ojamaa K 2000, The cardiovascular system in hypothyroidism. In: Braverman LE, Utiger RD, eds. *Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text*, edit. 8. Philadelphia: Lippincott Williams & Wilkins; 777–782.
- Klein I, Ojamaa K 2001, Thyroid hormone and the cardiovascular system. *N Engl J Med* 344:501–509.
- Klemperer JD, Klein I, Gomez M, et al. 1995, Thyroid hormone treatment after coronary-artery bypass surgery. *N Engl J Med* 333:1522–1527.
- Lacoviello M, Guida P. et al. 2008, Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. *Curr. Pharm Des.* 14(26):2686-92.
- Ladenson PW 1993, Thyrotoxicosis and heart: something old and something new. *J Clin Endocrinol Metab* 77:332–333.
- Ladenson PW, Sherman SI, Boughman RL, et al. 1992, Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. *Proc Natl Acad Sci USA* 89:5251–5255.
- Lekakis J, Papamichael C, Alevizaki M, et al. 1997, Flow-mediated, endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. *Thyroid* 7:411–414.
- Levey GS, Klein I 1990, Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. *Am J Med* 88:642–646.

- Lewis BS, Ehrenfeld EN, Lewis N, et al. 1979, Echocardiographic LV function in thyrotoxicosis. *Am Heart J* 97:460–468.
- Luboshitzky R, Aviv A, Herer P, et al. 2002, Risk factors for cardiovascular disease in women with subclinical hypothyroidism. *Thyroid* 12:421–425.
- Magner J, Clark W, Allenby P 1988, Congestive heart failure and sudden death in a young woman with thyrotoxicosis. *West J Med* 110:759–760.
- McAllister RM, Delp MD, Loughlin MH 1995, Thyroid status and exercise tolerance. Cardiovascular and metabolic consideration. *Sport Med* 20:189–198.
- McDermott MT, Ridgway EC 2001, Subclinical hypothyroidism is mild thyroid failure and should be treated. *J Clin Endocrinol Metab* 86:4585–4590.
- McDermott MM, Feinglass J, Sy J, et al. 1995, Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. *Am J Med* 99:629–635.
- Mercuro G, Panzuto MG, Bina A, et al. 2000, Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. *J Clin Endocrinol Metab* 85:159–164.
- Mintz G, Pizzarello R, Klein I 1991, Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. *J Clin Endocrinol Metab* 73:146–150.
- Monzani F, Di Bello V, Caraccio N, et al. 2001, Effects of levo-thyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. *J Clin Endocrinol Metab* 86:1110–1115.
- Morkin E 1993, Regulation of myosin heavy chain genes in the heart. *Circulation* 87:1451–1460.
- Morkin E, Pennock GD, Spooner PH, et al. 2002, Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. *Thyroid* 12:527–533.
- Moruzzi P, Doria E, Agostoni PG 1996. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. *Am J Med* 101:461–467.
- Müller B, Tsakiris DA, Roth CB, et al. 2001, Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. *Eur J Clin Invest* 31:131–137.
- Mullis-Janson SL, Argenziano M, Corwin S, et al. 1999, A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. *J Thorac Cardiovasc Surg* 117:1128–1134.
- Napoli R, Biondi B, Guardasole V, et al. 2001, Impact of hyperthyroidism and its correction on vascular reactivity in humans. *Circulation* 104:3076–3080.
- Nordyke RA, Gilbert FI Jr, Harada AS 1988, Graves' disease. Influence of age on clinical findings. *Arch Intern Med* 148:626–631.
- Obuobie K, Smith J, Evans LM, et al. 2002, Increased central arterial stiffness in hypothyroidism. *J Clin Endocrinol Metab* 87:4662–4666.

- Ojamaa K, Klemperer JD, Klein I 1996a, Acute effects of thyroid hormone on vascular smooth muscle. *Thyroid* 6:505–512.
- Ojamaa K, Klemperer JD, MacGilvray SS, et al. 1996b, Thyroid hormone and hemodynamic regulation of beta-myosin heavy chain promoter in the heart. *Endocrinology* 137:802–808.
- Ojamaa K, Sabet A, Kenessey A, Shenoy R, et al. 1999, Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. *Endocrinology* 140:3170–3176.
- Ojamaa K, Klein I, Sabet A, Steinberg SF 2000, Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. *Metabolism* 49:275–279.
- Ojamaa K, Kenessey A, Klein I 2002, Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. *Endocrinology* 141:2139–2144.
- Park KW, Dai HB, Ojamaa K, et al. 1997, The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. *Anesth Analg* 85:734–738.
- Parle JV, Maisonneuve P, Sheppard MC, et al. 2001, Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. *Lancet* 358:861–865.
- Petersen P, Hansen JM 1988, Stroke in thyrotoxicosis with atrial fibrillation. *Stroke* 19:15–18.
- Pingiatore A, Lervasi G, et al. 2005, Thyroid function and heart failure: from the new clinical evidences to the potential therapeutic implications. *Recent Prog Med*. 96(11):535-41.
- Resnick LM, Laragh JH 1982, Plasma renin activity in syndromes of thyroid hormone excess and deficiency. *Life Sci* 30:585–586.
- Rodondi N, Wendy P, et al. 2010, Subclinical Hypothyroidism and Riskn of Coronary Heart Disease and Mortality. *JAMA* Vol 304.No 12.
- Sawin CT, Geller A, Wolf PA, et al. 1994, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 331:1249–125.